3035547-78-2
Chemical Structure
ErSO-TFPy
Synonym(s): TEQ103; Sera2
- CAS No.: 3035547-78-2
- Formula:C19H13F7N2O2
- Molecular Weight:434.31
IUPAC Name: (R)-3-(4-hydroxyphenyl)-3-(3,3,4,4-tetrafluoropyrrolidin-1-yl)-7-(trifluoromethyl)indolin-2-one
InChIKey: PSTKCYQKNLKUBN-GOSISDBHSA-N
SMILES: O=C1[C@@](N2CC(F)(C(F)(C2)F)F)(C3=CC=C(C=C3)O)C4=CC=CC(C(F)(F)F)=C4N1
Biological Activity: ErSO-TFPy (TEQ103) is an ERα+ tumor cell inhibitor with low nanomolar cytotoxic activity against ERα+ breast cancer cells. ErSO-TFPy activates the sodium channel TRPM4, causes an imbalance of intracellular calcium and sodium ions. ErSO-TFPy dysregulates calcium homeostasis in ERα+ tumor cells, triggers the anticipatory unfolded protein response, and induces rapid immune cell-independent necrotic cell death. ErSO-TFPy can be used for the research of estrogen receptor alpha positive breast cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ErSO-TFPy | 99.33% | ErSO-TFPy (TEQ103) is an ERα+ tumor cell inhibitor with low nanomolar cytotoxic activity against ERα+ breast cancer cells. ErSO-TFPy activates the sodium channel TRPM4, causes an imbalance of intracellular calcium and sodium ions. ErSO-TFPy dysregulates calcium homeostasis in ERα+ tumor cells, triggers the anticipatory unfolded protein response, and induces rapid immune cell-independent necrotic cell death. ErSO-TFPy can be used for the research of estrogen receptor alpha positive breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Marie-Christine Bissery, et al. Abstract 5629_ TEQ103, a novel therapeutic for the treatment of estrogen receptor alpha positive (ERα+) breast cancer. Cancer Res (2025) 85 (8_Supplement_1): 5629.
- [2]. Mulligan MP, et al. Single Dose of a Small Molecule Leads to Complete Regressions of Large Breast Tumors in Mice. ACS Cent Sci. 2025;11(2):228-238. Published 2025 Jan 22. [Content Brief]
Keywords
